OTCMKTS:MYRX

Myrexis Competitors

$0.05
0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.05
$0.06
52-Week Range
$0.01
$0.08
Volume200 shs
Average Volume43,829 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta2.53

Competitors

Myrexis (OTCMKTS:MYRX) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying MYRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Myrexis, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Acusphere and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Volatility and Risk

Acusphere has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Acusphere and Myrexis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Myrexis0000N/A

Profitability

This table compares Acusphere and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
MyrexisN/AN/AN/A

Summary

Myrexis beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Affymax has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Valuation and Earnings

This table compares Affymax and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Profitability

This table compares Affymax and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
MyrexisN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Affymax and Myrexis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Myrexis0000N/A

Summary

Affymax beats Myrexis on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

ARYx Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares ARYx Therapeutics and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
MyrexisN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for ARYx Therapeutics and Myrexis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Myrexis0000N/A

Summary

Myrexis beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

AtheroNova has a beta of -8.71, suggesting that its stock price is 971% less volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Profitability

This table compares AtheroNova and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
MyrexisN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for AtheroNova and Myrexis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
Myrexis0000N/A

Summary

Myrexis beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Myrexis (OTCMKTS:MYRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

China Botanic Pharmaceutical has a beta of 17.09, suggesting that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Profitability

This table compares China Botanic Pharmaceutical and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
MyrexisN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for China Botanic Pharmaceutical and Myrexis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Myrexis0000N/A

Summary

China Botanic Pharmaceutical beats Myrexis on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Myrexis (OTCMKTS:MYRX) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for China Dongsheng International and Myrexis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
Myrexis0000N/A

Volatility & Risk

China Dongsheng International has a beta of 13.38, suggesting that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Myrexis has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Earnings & Valuation

This table compares China Dongsheng International and Myrexis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
MyrexisN/AN/AN/AN/AN/A

Profitability

This table compares China Dongsheng International and Myrexis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
MyrexisN/AN/AN/A

Summary

China Dongsheng International beats Myrexis on 1 of the 1 factors compared between the two stocks.


Myrexis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.79flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.06flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.